TG Therapeutics, Inc. (NASDAQ:TGTX) Receives $31.83 Consensus PT from Analysts

TG Therapeutics, Inc. (NASDAQ:TGTX) has been given an average recommendation of “Moderate Buy” by the six research firms that are covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a hold rating and five have given a buy rating to the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $31.83.

Several research firms recently weighed in on TGTX. HC Wainwright reiterated a “buy” rating and issued a $49.00 target price on shares of TG Therapeutics in a report on Tuesday, August 6th. The Goldman Sachs Group boosted their price objective on TG Therapeutics from $18.00 to $20.00 and gave the company a “neutral” rating in a report on Wednesday, August 7th. Finally, B. Riley lifted their target price on TG Therapeutics from $29.00 to $34.00 and gave the company a “buy” rating in a research report on Wednesday, August 7th.

TG Therapeutics Stock Performance

Shares of TG Therapeutics stock opened at $25.08 on Wednesday. The firm has a market cap of $3.88 billion, a PE ratio of 109.04 and a beta of 2.21. The company has a quick ratio of 2.83, a current ratio of 3.58 and a debt-to-equity ratio of 0.58. TG Therapeutics has a 52 week low of $6.46 and a 52 week high of $26.03. The business’s fifty day simple moving average is $21.73 and its 200-day simple moving average is $18.15.

TG Therapeutics (NASDAQ:TGTX) last announced its earnings results on Tuesday, August 6th. The biopharmaceutical company reported $0.04 earnings per share for the quarter, topping the consensus estimate of ($0.04) by $0.08. The company had revenue of $73.47 million during the quarter, compared to analyst estimates of $65.92 million. TG Therapeutics had a net margin of 27.60% and a return on equity of 57.73%. TG Therapeutics’s revenue was up 357.0% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.34) earnings per share. Equities analysts forecast that TG Therapeutics will post 0.13 earnings per share for the current year.

Institutional Investors Weigh In On TG Therapeutics

Several large investors have recently bought and sold shares of the stock. Pingora Partners LLC purchased a new stake in shares of TG Therapeutics during the fourth quarter worth approximately $27,000. Ashton Thomas Private Wealth LLC purchased a new stake in shares of TG Therapeutics in the 2nd quarter valued at approximately $35,000. DekaBank Deutsche Girozentrale acquired a new stake in shares of TG Therapeutics in the 1st quarter valued at $58,000. nVerses Capital LLC lifted its position in shares of TG Therapeutics by 34.9% during the 2nd quarter. nVerses Capital LLC now owns 5,800 shares of the biopharmaceutical company’s stock worth $103,000 after purchasing an additional 1,500 shares during the last quarter. Finally, Quarry LP grew its stake in shares of TG Therapeutics by 9.1% during the second quarter. Quarry LP now owns 6,003 shares of the biopharmaceutical company’s stock worth $107,000 after purchasing an additional 503 shares in the last quarter. Hedge funds and other institutional investors own 58.58% of the company’s stock.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.